REC-163964

Recursion has initiated the EXCELERIZE Phase 1 clinical trial of REC-3565, a selective MALT1 inhibitor designed to treat relapsed or refractory B-cell lymphomas.

Arvinas plans to initiate two Phase 3 trials in 2025 for vepdegestrant in ER+/HER2- metastatic breast cancer, one in the first-line setting with atirmociclib and another in the second-line setting with a CDK4/6 inhibitor.

Recursion Pharmaceuticals has initiated a Phase 2 clinical trial for REC-3964, a novel oral treatment for recurrent Clostridioides difficile infection, marking a significant step in addressing a condition that affects up to 175,000 individuals annually in the U.S.

Recursion's REC-3964, an AI-developed, non-antibiotic small molecule, has entered Phase II clinical trials for recurrent Clostridioides difficile (C. diff) infection.

Recursion initiated a Phase 2 clinical trial for REC-3964, a novel, non-antibiotic oral small molecule, targeting recurrent Clostridioides difficile infection.